Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Declines By 77.6%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant decline in short interest in April. As of April 30th, there was short interest totaling 112,316 shares, a decline of 77.6% from the April 15th total of 502,390 shares. Based on an average trading volume of 169,623 shares, the short-interest ratio is presently 0.7 days. Approximately 2.6% of the shares of the stock are short sold.

Galmed Pharmaceuticals Price Performance

NASDAQ GLMD traded up $0.01 during trading on Wednesday, hitting $0.60. 29,608 shares of the company’s stock traded hands, compared to its average volume of 165,306. The stock has a fifty day moving average of $0.62 and a two-hundred day moving average of $0.80. Galmed Pharmaceuticals has a 12-month low of $0.41 and a 12-month high of $2.34. The firm has a market cap of $3.26 million, a P/E ratio of -0.48 and a beta of 0.62.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.